Thesis as of Jun 23, 2026
Boundless Bio has discontinued its cancer programs and agreed to merge with Serapha Bio, whose SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency, is in an investigator-initiated trial in China.
Boundless Bio discontinued BBI-940, its last ecDNA cancer program, after early clinical data did not support further development, and agreed to an all-stock merger with Serapha Bio, expected to close in the fourth quarter of 2026. Pre-merger Boundless holders are expected to own about 3.7% of the combined company, which will be named Serapha Bio and trade as AATD, and to receive a cash dividend of about $44-48 million before closing. Its value would then rest on SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency in an investigator-initiated trial in China.
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the Thesis, argued
Pipeline
1 programs · 5 catalysts